Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 10  •  04:00PM ET
6.44
Dollar change
+0.17
Percentage change
2.71
%
Index- P/E- EPS (ttm)-0.71 Insider Own35.92% Shs Outstand65.02M Perf Week1.90%
Market Cap418.75M Forward P/E- EPS next Y-0.81 Insider Trans0.00% Shs Float41.67M Perf Month25.78%
Enterprise Value289.93M PEG- EPS next Q-0.20 Inst Own70.12% Short Float7.23% Perf Quarter75.48%
Income-62.52M P/S- EPS this Y-32.50% Inst Trans8.12% Short Ratio4.73 Perf Half Y356.74%
Sales0.00M P/B3.87 EPS next Y-1.89% ROA-37.55% Short Interest3.01M Perf YTD22.90%
Book/sh1.66 P/C3.01 EPS next 5Y-3.66% ROE-47.86% 52W High6.88 -6.40% Perf Year287.95%
Cash/sh2.14 P/FCF- EPS past 3/5Y- - ROIC-57.76% 52W Low0.97 563.92% Perf 3Y-37.05%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility11.23% 11.55% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-19.69% Oper. Margin- ATR (14)0.56 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.58 Sales Y/Y TTM- Profit Margin- RSI (14)61.50 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio5.58 EPS Q/Q19.34% SMA209.94% Beta0.20 Target Price15.86
Payout- Debt/Eq0.00 Sales Q/Q- SMA5029.02% Rel Volume0.88 Prev Close6.27
Employees30 LT Debt/Eq0.00 EarningsNov 13 BMO SMA200124.10% Avg Volume637.20K Price6.44
IPOSep 03, 2021 Option/ShortYes / Yes EPS/Sales Surpr.-9.78% - Trades Volume559,834 Change2.71%
Date Action Analyst Rating Change Price Target Change
Feb-09-26Initiated Wedbush Outperform $15
Nov-04-24Initiated Leerink Partners Outperform $15
Sep-05-24Initiated H.C. Wainwright Neutral $5
May-03-24Initiated Piper Sandler Overweight $26
Oct-10-23Initiated Ladenburg Thalmann Buy $10
Aug-25-23Initiated Oppenheimer Outperform $17
Jun-22-23Initiated Guggenheim Buy $20
Jun-14-23Initiated Chardan Capital Markets Buy $14
May-24-23Initiated Raymond James Strong Buy $20
Feb-04-26 06:30AM
Jan-21-26 08:50AM
Jan-12-26 06:30AM
Nov-29-25 01:26AM
Nov-13-25 06:30AM
06:30AM Loading…
Aug-20-25 06:30AM
Aug-14-25 08:15AM
Jul-17-25 04:30PM
Jul-01-25 06:30AM
May-27-25 06:30AM
May-20-25 06:30AM
May-08-25 06:30AM
Mar-25-25 06:30AM
Feb-24-25 06:30AM
Dec-23-24 06:30AM
06:30AM Loading…
Nov-25-24 06:30AM
Nov-14-24 04:30PM
Nov-07-24 06:30AM
Oct-30-24 06:30AM
Sep-03-24 06:00AM
Aug-13-24 09:21AM
Aug-12-24 04:05PM
Aug-09-24 04:05PM
Aug-01-24 08:00AM
Jul-12-24 06:10AM
06:08AM
Jun-14-24 06:00AM
Jun-06-24 06:00AM
Jun-03-24 06:00AM
May-31-24 09:55AM
06:00AM Loading…
May-29-24 06:00AM
May-24-24 06:18AM
May-15-24 09:55AM
May-14-24 12:00PM
May-12-24 03:26PM
May-10-24 03:14PM
May-09-24 01:56PM
06:00AM
Apr-25-24 02:18AM
Apr-18-24 09:22AM
Apr-08-24 06:00AM
Mar-28-24 11:54AM
06:00AM
Mar-04-24 06:00AM
Feb-02-24 06:00AM
Jan-08-24 06:00AM
Jan-03-24 06:00AM
Dec-04-23 06:00AM
Nov-14-23 06:00AM
Nov-13-23 06:30AM
Sep-12-23 05:00AM
Sep-05-23 08:55PM
Aug-25-23 09:42AM
Aug-14-23 07:00AM
Jun-23-23 06:30AM
Jun-06-23 06:34AM
04:00AM
Jun-01-23 10:20AM
Apr-27-23 07:39AM
Apr-14-23 05:00AM
Mar-27-23 09:35AM
Mar-21-23 06:13AM
Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.